RAPT Therapeutics Inc (NASDAQ:RAPT) — Market Cap & Net Worth
Market Cap & Net Worth: RAPT Therapeutics Inc (RAPT)
RAPT Therapeutics Inc (NASDAQ:RAPT) has a market capitalization of $1.68 Billion ($1.68 Billion) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6920 globally and #2074 in its home market, demonstrating a 0.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RAPT Therapeutics Inc's stock price $58.01 by its total outstanding shares 28960580 (28.96 Million). Review how much debt does RAPT Therapeutics Inc carry to assess the company's total debt and financial obligations.
RAPT Therapeutics Inc Market Cap History: 2019 to 2026
RAPT Therapeutics Inc's market capitalization history from 2019 to 2026. Data shows growth from $799.60 Million to $1.68 Billion (26.55% CAGR).
Index Memberships
RAPT Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.07% | #185 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #752 of 3165 |
Weight: RAPT Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
RAPT Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RAPT Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
375.52x
RAPT Therapeutics Inc's market cap is 375.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $799.60 Million | $935.00K | -$43.00 Million | 855.19x | N/A |
| 2020 | $571.97 Million | $5.04 Million | -$52.89 Million | 113.44x | N/A |
| 2021 | $1.06 Billion | $3.81 Million | -$68.21 Million | 278.97x | N/A |
| 2022 | $573.42 Million | $1.53 Million | -$81.88 Million | 375.52x | N/A |
Competitor Companies of RAPT by Market Capitalization
Companies near RAPT Therapeutics Inc in the global market cap rankings as of June 18, 2026.
Key companies related to RAPT Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
RAPT Therapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, RAPT Therapeutics Inc's market cap moved from $799.60 Million to $ 1.68 Billion, with a yearly change of 26.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.68 Billion | +71.26% |
| 2025 | $980.89 Million | +2043.67% |
| 2024 | $45.76 Million | -93.64% |
| 2023 | $719.67 Million | +25.51% |
| 2022 | $573.42 Million | -46.09% |
| 2021 | $1.06 Billion | +85.97% |
| 2020 | $571.97 Million | -28.47% |
| 2019 | $799.60 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of RAPT Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.68 Billion USD |
| MoneyControl | $1.68 Billion USD |
| MarketWatch | $1.68 Billion USD |
| marketcap.company | $1.68 Billion USD |
| Reuters | $1.68 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more